Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed SCLC with MGMT methylation.~* Patient previously treated by one or two chemotherapy lines.~* Age ≤ 75 and Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.~* Patients must have measurable disease, defined as at least one lesion than can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20mm with conventional techniques or as \>10mm with spiral CT scan.~* Patient with controlled brain metastases are eligible.~* Patient previously treated with chest and/or brain RT are eligible.~* Life expectancy \>3 months.~* Patient must have normal organ and marrow function as defined below: leukocytes \>3,000/μL, absolute neutrophil count \>1,000/μL, platelets\>100,000/μL, total bilirubin within normal institutional limits, AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal, creatinine within normal institutional limits~* Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Histologically or cytologically confirmed SCLC without MGMT methylation.~* Patients who have received three or more previous chemotherapy lines for small cell lung cancer or radiotherapy on target lesions.~* Symptomatic uncontrolled CNS metastasis.~* Participation in another clinical trial with any investigational agents within 30 days prior to study screening.~* Presence of infection.~* History or evidence of malabsorption syndrome or disease that may significantly affect gastrointestinal function.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or other agents used in the study.~* Presence of medical problems of sufficient severity to prevent full compliance with the study.~* Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal

Based on this trial design, predict the completion outcome and termination type (if applicable).